Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Aytu BioPharma Inc. (AYTU) had Revenue of $13.89M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$13.89M
Net Income	$1.97M
Cost of Goods Sold	$4.70M
Gross Profit	$9.19M
Operating Expenses	$15.39M
Operating Income	$-1.50M
Non-Operating Income/Expense	$3.47M
Pre-Tax Income	$1.97M
Normalized Pre-Tax Income	$1.97M
Income after Taxes	$1.97M
Income from Continuous Operations	$1.97M
Consolidated Net Income/Loss	$1.97M
Normalized Income after Taxes	$1.97M
EBIT	$-1.50M
EBITDA	$-0.67M
Weighted-Average Shares Outstanding (Basic)	9.44M
Weighted-Average Shares Outstanding (Diluted)	19.48M
Earnings per Share (EPS) (Basic)	$0.21
Earnings per Share (EPS) (Diluted)	$-0.08
Balance Sheet Financials
Current Assets	$81.11M
Property, Plant, and Equipment	$0.50M
Long-Term Assets	$43.88M
Total Assets	$124.99M
Current Liabilities	$65.99M
Long-Term Debt	$10.45M
Long-Term Liabilities	$35.82M
Total Liabilities	$101.82M
Common Equity	$23.17M
Tangible Shareholders Equity	$-18.26M
Shareholders Equity	$23.17M
Common Shares Outstanding	9.91M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-0.62M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$2.30M
Beginning Cash	$30.95M
End Cash	$32.63M
Increase/Decrease in Cash	$1.68M
Stock-Based Compensation	$0.11M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.23
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.31
Debt to Equity Ratio	1.17
Gross Margin	66.14%
Operating Margin	-10.83%
EBIT Margin	-10.83%
EBITDA Margin	--
Pre-Tax Profit Margin	14.15%
Profit Margin	14.15%
Free Cash Flow	$-0.62M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.11
Inventory Turnover	0.47
Receiveable Turnover	0.42
Days Sales in Receivables	215.31
Return on Equity	8.48%
Return on Tangible Equity	-10.76%
Return on Assets	1.57%
Return on Investments	5.85%
Book Value Per Share	$2.34
Free Cash Flow per Share	$-0.03
Operating Cash Flow per Share	$-0.03

Data from Zacks Investment Research, Inc.